BJMO - 2021, issue 3, march 2021
Hannah Van Belle , Hans Wildiers
Background: Docetaxel, carboplatin and trastuzumab, with or without pertuzumab (TCH(P)), is increasingly used for (neo) adjuvant treatment of HER2-positive early breast cancer. However, its associated febrile neutropenia (FN) risk is unclear: pivotal studies reported FN risks <10%, but in clinical practice a high FN rate (>20%) was observed. This systematic review and meta-analysis determine the FN risk associated with TCH(P) and the effect of primary prophylactic granulocyte colony-stimulating factor (PP G-CSF).
Read moreBJMO - 2021, issue 3, march 2021
Sofie Demasure , Isabel Spriet , Philip R. Debruyne , Annouschka Laenen , Wim Wynendaele , Marcella Baldewijns , Herlinde Dumez , Paul M. Clement , Hans Wildiers , Patrick Schöffski , Eduard Rousse , Lisa Kinget , Maarten Albersen , Benoit Beuselinck
Introduction: Only a limited number of recent phase III studies with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), mTOR-inhibitors or immune checkpoint inhibitors (ICI) in metastatic clear-cell renal cell carcinoma (m-ccRCC) could show an overall survival (OS) benefit compared to standard of care. We aimed to study the evolution of OS of m-ccRCC patients during the last 20-years period (2000–2020).
Read moreBJMO - 2021, issue 3, march 2021
Thomas Meyskens , Iris Timmermans , Hans Wildiers , Herlinde Dumez , Daphne Hompes , Melissa Christiaens , Raf Sciot , Annouschka Laenen , Jerry Lee , Patrick Schöffski
Objective: Angiosarcoma (AS) is a rare, aggressive subtype of soft tissue sarcoma (STS). Treatment requires a multidisciplinary approach and should preferably be carried out in reference centers. We performed an in-depth analysis of patient characteristics, treatments and prognostic factors in patients (pts) with AS treated at the University Hospitals Leuven (Belgium).
Read more